Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Lilly’s retatrutide creeps closer to market for sleep apnea

Expectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining up data in other indications with the aim of eventually ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

China eases uncertainty over offshore trust taxes before grace period ends

China’s tax authorities are accepting reasonable explanations when enforcing new rules on offshore trust gains, according to an executive who says their appeal was successful, offering some reassurance as a 90-day grace period expires on Thursday. The approach appears to be translating into greater clarity from regulators.

More from Wednesday 21 October →